OverviewSuggest Edit

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products.

TypePublic
Founded2001
HQWien, AT
Websitenabriva.com

Latest Updates

Employees (est.) (Jan 2020)162(+48%)
Revenue (FY, 2020)$5 M(-46%)
Share Price (Mar 2021)$1.6(-1%)
Cybersecurity ratingAMore

Key People/Management at Nabriva Therapeutics

Daniel Burgess

Daniel Burgess

Director
Charles Rowland

Charles Rowland

Director
Ted Schroeder

Ted Schroeder

Chief Executive Officer
Robert Crotty

Robert Crotty

General Counsel
Steven Gelone

Steven Gelone

President & Chief Operating Officer
Jennifer Schranz

Jennifer Schranz

Chief Medical Officer
Show more

Nabriva Therapeutics Office Locations

Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin 1 and Dublin 4
Wien, AT (HQ)
Leberstrasse 20
Dublin 1, IE
25 N Wall Quay, North Wall
Dublin 4, IE
The Sweepstakes, Ballsbridge Park, Merrion Rd
King of Prussia, PA, US
1000 Continental Dr #600
Show all (4)

Nabriva Therapeutics Financials and Metrics

Nabriva Therapeutics Revenue

Nabriva Therapeutics's revenue was reported to be $5.03 m in FY, 2020
USD

Revenue (FY, 2020)

5.0m

Gross profit (FY, 2020)

4.3m

Gross profit margin (FY, 2020), %

84.8%

Net income (FY, 2020)

(69.5m)

EBIT (FY, 2020)

(66.1m)

Market capitalization (30-Mar-2021)

57.4m

Closing stock price (30-Mar-2021)

1.6

Cash (31-Dec-2020)

41.4m

EV

23.8m
Nabriva Therapeutics's current market capitalization is $57.4 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

9.7m9.5m5.0m

Cost of goods sold

70.0k766.0k

Gross profit

9.4m4.3m

Gross profit Margin, %

99%85%
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020

Revenue

7.6m847.0k461.0k1.7m525.0k6.9m789.0k1.3m

Cost of goods sold

15.0k8.0k25.0k

Gross profit

6.9m781.0k1.3m

Gross profit Margin, %

100%99%98%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

32.8m86.8m102.0m86.0m41.4m

Accounts Receivable

2.7m3.9m

Prepaid Expenses

1.2m1.6m1.2m1.2m5.9m

Inventories

682.0k5.8m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

27.2m20.1m112.2m89.4m75.3m100.3m91.0m58.7m78.1m26.9m49.7m41.1m

Accounts Receivable

6.5m3.5m3.2m3.4m

Prepaid Expenses

903.0k1.4m1.5m1.0m1.2m1.2m973.0k1.4m1.2m2.9m3.9m3.8m

Inventories

162.0k4.2m5.2m5.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(54.9m)(74.4m)(114.8m)(82.8m)(69.5m)

Depreciation and Amortization

233.0k432.0k510.0k396.0k417.0k

Inventories

(682.0k)(5.1m)

Accounts Payable

(383.0k)2.6m(3.0m)1.3m(1.8m)
Quarterly
USDFY, 2016

Financial Leverage

1.2 x
Show all financial metrics

Nabriva Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Zavante Therapeutics IncJuly 25, 2018$124 m

Nabriva Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Nabriva Therapeutics Online and Social Media Presence

Embed Graph

Nabriva Therapeutics News and Updates

Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Dani…

Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary …

Nabriva Therapeutics Announces Proposed Public Offering

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has commenced a…

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

-Amended agreement encompasses enhanced manufacturing collaboration and regulatory support

Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split

DUBLIN, Ireland, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock spl…

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship
Show more

Nabriva Therapeutics Blogs

Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.

- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa. , April 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the

WEP Clinical Expands Availability Of Xenleta® (Lefamulin) Named Patient Program In Partnership With Nabriva Therapeutics

March 24 at 8:00 AM EDT WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA® (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa. NPP is designed to ensure that physicians can request IV or oral

Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates

Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates Content Import Thu, 03/11/2021 - 16:10 Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates March 11, 2021…

Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021

DUBLIN, Ireland , March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full

Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Content Import Mon, 03/01/2021 - 08:03 Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules March 1, 202…

Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January

DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will
Show more

Nabriva Therapeutics Frequently Asked Questions

  • When was Nabriva Therapeutics founded?

    Nabriva Therapeutics was founded in 2001.

  • Who are Nabriva Therapeutics key executives?

    Nabriva Therapeutics's key executives are Daniel Burgess, Charles Rowland and Ted Schroeder.

  • How many employees does Nabriva Therapeutics have?

    Nabriva Therapeutics has 162 employees.

  • What is Nabriva Therapeutics revenue?

    Latest Nabriva Therapeutics annual revenue is $5 m.

  • What is Nabriva Therapeutics revenue per employee?

    Latest Nabriva Therapeutics revenue per employee is $31 k.

  • Who are Nabriva Therapeutics competitors?

    Competitors of Nabriva Therapeutics include Chiesi Espana, Medicago and Cell Signaling Technology.

  • Where is Nabriva Therapeutics headquarters?

    Nabriva Therapeutics headquarters is located at Leberstrasse 20, Wien.

  • Where are Nabriva Therapeutics offices?

    Nabriva Therapeutics has offices in Wien, King of Prussia, Dublin 1 and Dublin 4.

  • How many offices does Nabriva Therapeutics have?

    Nabriva Therapeutics has 4 offices.